Business Context and Reporting Period
This Form 6-K filing covers the month of March 2023 for Midatech Pharma PLC (intending to change its name to Biodexa Pharmaceuticals plc). The registrant is a foreign private issuer based in Cardiff, United Kingdom, with American Depositary Shares listed on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and does not contain financial performance data.
Material Changes and Corporate Actions
The Company announced a General Meeting scheduled for March 24, 2023, to seek shareholder approval for the following material changes:
- A one-for-20 reverse stock split of ordinary shares.
- A change of the Company's name to "Biodexa Pharmaceuticals plc."
- The cancellation of the listing of Ordinary Shares on the London Stock Exchange's AIM market (AIM Cancellation).
- Adoption of new Articles of Association and authority to allot shares.
If approved, the Company will retain its listing on the NASDAQ Capital Market.
Outlook, Risks, and Management Commentary
Management has issued a Circular and a set of Frequently Asked Questions regarding the proposed delisting from AIM. The filing notes that the information is being furnished and not deemed "filed" under Section 18 of the Exchange Act, except as incorporated by reference into specific registration statements (Form S-8 and Form F-3). No specific financial guidance or operational outlook was provided in this text.
Investor Verification Checklist
- Verify the outcome of the General Meeting scheduled for March 24, 2023, regarding the reverse stock split and name change.
- Confirm the status of the AIM delisting and the continued listing on the NASDAQ Capital Market.
- Review the attached Circular (Exhibit 99.1) for detailed terms of the reverse stock split and new Articles of Association.
- Check subsequent filings for the first financial report under the new corporate name, Biodexa Pharmaceuticals plc.